PubMed
Melanotan II and its molecular mechanisms
Dorr RT, Dawson BV, Hadley ME, et al. Life Sci. 2009
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.01–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 94% said they felt similar to their last entry, 6% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 50 days · Based on 32 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 59% · Mixed 28% · Unfavorable overall 13%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.025–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 54% said they felt similar to their last entry, 33% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 19 days · Based on 212 repeat reporters
Published sources linked on the Melanotan II and Wolverine Blend wiki pages.
PubMed
Dorr RT, Dawson BV, Hadley ME, et al. Life Sci. 2009
PubMed
Mestria S, Odoardi S, Frison G, et al. Drug testing and analysis. 2021
PubMed
Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.). 2012
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010